[A new anti-inflammatory--analgesic--antipyretic for the treatment of acute disease of the bronchi ].

Riv Eur Sci Med Farmacol

Istituto di Clinica Tisiologica e Malattie Respiratorie, Università di Messina.

Published: December 1990

Sixty adult patients, 31 men and 29 women, aged 44 to 60, and affected by acute bronchitis of probable bacterial aetiology were randomly divided into 3 groups of 20 and treated respectively with: 1) morniflumate (one 700 mg tablet twice a day) + amoxicillin (one 1 g tablet twice a day); 2) feprazone (one 200 mg tablet twice a day) + amoxicillin (one 1 g tablet twice a day); 3) amoxicillin (one 1 g tablet twice a day). Mean therapy duration was 9 days. The action of the drugs under study was assessed by objective chest examination and by evaluating the modifications of cough intensity and frequency, chest pain expectorating difficulty, amount of expectoration, body temperature. The overall assessments were completed by side-effect recording and by laboratory examinations carried out at the beginning and end of the study. Checks were made regularly on admission, and in the 3rd, 5th, 7th and last day of therapy. The above mentioned parameters showed a quicker regression of bronchial inflammation in the subjects treated also with the antiinflammatory drug compared to those treated only with the antibiotic. Furthermore, in the subjects treated with morniflumate such improvement was more rapidly achieved compared to those who received feprazone. The analgesic and antipyretic effects of morniflumate were also remarkable. All tested drugs were well tolerated.

Download full-text PDF

Source

Publication Analysis

Top Keywords

tablet day
20
day amoxicillin
12
amoxicillin tablet
12
treated morniflumate
8
day therapy
8
subjects treated
8
day
6
tablet
5
anti-inflammatory--analgesic--antipyretic treatment
4
treatment acute
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!